Biotech

All Articles

AstraZeneca posts information on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early look at the performance of its own internal antibody-drug conju...

iTeos- GSK's TIGIT superstar reveals meaningful enhancement

.After announcing a period 3 launch based upon good midstage results, iTeos as well as GSK are final...

More collaborative FDA may increase unusual disease R&ampD: document

.The FDA should be actually even more open and collective to unleash a rise in commendations of rare...

Zenas, MBX, Bicara head to Nasdaq in warm day for biotech IPOs

.It's an unusually active Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapies al...

Atea's COVID antiviral neglects to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has failed another COVID-19 test, yet the biotech still holds out h...

Neurocrine's proposal to save schizophrenia possibility neglects

.Neurocrine Biosciences' schizophrenia plan pivot has fallen short. The biotech was incapable to rep...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has brought in an overdue access to the radioligand party, paying for one hundred thousand e...

F 2G raises $100M for second try to get new antifungal to market

.After F2G's initial attempt to acquire a brand-new lesson of antifungal to market was derailed by t...

Moderna targets $1.1 B in R&ampD investing cuts, falls 5 programs surrounded by success pressures

.Moderna has sworn to reduce R&ampD spending by $1.1 billion through 2027. The decision to retract t...

Sanofi's $80M bet on Key dystrophy medication finishes in stage 3 fail

.Simply 4 months after Sanofi bet $80 thousand in beforehand money on Pivot Therapies' losmapimod, t...